Search Results | Clinical Cancer Research | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Anne Montfort, Thomas Filleron, Mathieu Virazels, Carine Dufau, Jean Milhès, Cécile Pagès, Pascale Olivier, Maha Ayyoub, Muriel Mounier, Amélie Lusque, Stéphanie Brayer, Jean-Pierre Delord, Nathalie Andrieu-Abadie, Thierry Levade, Céline Colacios, Bruno Ségui, Nicolas Meyer

Clin Cancer Res (2021) 27 (4): 1037–1047.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-3449

Published: 15 February 2021

View article

Includes: Supplementary data

Journal Articles

Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers

Maha Ayyoub, Pascale Pignon, Danijel Dojcinovic, Isabelle Raimbaud, Lloyd J. Old, Immanuel Luescher, Danila Valmori

Clin Cancer Res (2010) 16 (18): 4607–4615.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-1485

Published: 14 September 2010

View article

Journal Articles

Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4⁺ T Cell Responses with a Conserved T Cell Receptor Repertoire

Gilles Bioley, Christelle Dousset, Alice Yeh, Bo Dupont, Nina Bhardwaj, Gregory Mears, Lloyd J. Old, Maha Ayyoub, Danila Valmori

Clin Cancer Res (2009) 15 (13): 4467–4474.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-0582

Published: 01 July 2009

View article

Journal Articles

HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine

Gilles Bioley, Philippe Guillaume, Immanuel Luescher, Alice Yeh, Bo Dupont, Nina Bhardwaj, Gregory Mears, Lloyd J. Old, Danila Valmori, Maha Ayyoub

Clin Cancer Res (2009) 15 (1): 299–306.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-1747

Published: 31 December 2008

View article

Includes: Supplementary data

Journal Articles

Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4⁺ T Cells

Danila Valmori, Feng Qian, Maha Ayyoub, Christoph Renner, Andrea Merlo, Sacha Gjnatic, Elisabeth Stockert, Deborah Driscoll, Shashikant Lele, Lloyd J. Old, Kunle Odunsi

Clin Cancer Res (2006) 12 (2): 398–404.

DOI: https://doi.org/10.1158/1078-0432.CCR-05-1902

Published: 20 January 2006

View article

Journal Articles

Activation of Human Melanoma Reactive CD8+ T Cells by Vaccination with an Immunogenic Peptide Analog Derived from Melan-A/Melanoma Antigen Recognized by T Cells-1

Maha Ayyoub, Alfred Zippelius, Mikaël J. Pittet, Donata Rimoldi, Danila Valmori, Jean-Charles Cerottini, Pedro Romero, Ferdy Lejeune, Danielle Liénard, Daniel E. Speiser

Clin Cancer Res (2003) 9 (2): 669–677.

Published: 01 February 2003

View article

NARROW

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers

Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4⁺ T Cell Responses with a Conserved T Cell Receptor Repertoire

HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine

Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4⁺ T Cells

Activation of Human Melanoma Reactive CD8+ T Cells by Vaccination with an Immunogenic Peptide Analog Derived from Melan-A/Melanoma Antigen Recognized by T Cells-1

Email alerts

AACR Journals

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers

Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire

HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine

Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells

Activation of Human Melanoma Reactive CD8+ T Cells by Vaccination with an Immunogenic Peptide Analog Derived from Melan-A/Melanoma Antigen Recognized by T Cells-1

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4⁺ T Cell Responses with a Conserved T Cell Receptor Repertoire

Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4⁺ T Cells